Literature DB >> 26519284

An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis.

Akiko Hisamochi1, Masayoshi Kage2, Tatsuya Ide3, Teruko Arinaga-Hino3, Keisuke Amano3, Reiichiro Kuwahara3, Kei Ogata3, Ichiro Miyajima3, Ryukichi Kumashiro3,4, Michio Sata5, Takuji Torimura3.   

Abstract

BACKGROUND: Drug-induced liver injury (DILI) sometimes resembles autoimmune hepatitis (AIH) in its hepatic histology. However, there is lacking data of a comparison of the characteristics between such DILI and DILI without histological findings like AIH.
METHODS: We enrolled 62 patients with DILI who were diagnosed using the Roussel Uclaf Causality Assessment Method, and performed a liver biopsy. These patients were classified into two groups: DILI with histology like AIH (group A, n = 23) and DILI without such histology (group B, n = 39). Sixteen patients of group A could be further classified into two groups: patients with relapse of the liver injury (group C, n = 8) and without relapse (group D, n = 8), after the recovery of the DILI. We compared the clinical and histological findings between group A and B, and group C versus D.
RESULTS: Group A was characterized by an older age (p = 0.043), higher immunoglobulin G level (p = 0.017), positive antinuclear antibody status (p = 0.044), and a higher frequency of complementary alternative medicines and Chinese herbal medicines as the causative drug (p = 0.008). There were no significant differences between group C and D regarding the clinical data and liver histological findings.
CONCLUSIONS: The clinical characteristics of DILI, which showed histological findings similar to AIH, were revealed. In such patients, a liver biopsy is recommended in order to determine the appropriate treatment strategy. In DILI with histology like AIH patients, long-term follow-up is needed to perceive the relapse.

Entities:  

Keywords:  Autoimmune hepatitis; Complementary alternative medicines; Drug-induced liver injury; Liver histology; Relapsed case

Mesh:

Year:  2015        PMID: 26519284     DOI: 10.1007/s00535-015-1131-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  31 in total

1.  Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors.

Authors:  C Bachmeyer; J F Cadranel
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

Review 2.  Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease.

Authors:  M P Manns; P Obermayer-Straub
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

3.  Autoimmune hepatitis triggered by statins.

Authors:  Vamsee Alla; Joseph Abraham; Junaid Siddiqui; Dimple Raina; George Y Wu; Naga P Chalasani; Herbert L Bonkovsky
Journal:  J Clin Gastroenterol       Date:  2006-09       Impact factor: 3.062

Review 4.  Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis.

Authors:  M A Robin; M Le Roy; V Descatoire; D Pessayre
Journal:  J Hepatol       Date:  1997       Impact factor: 25.083

5.  Autoimmune hepatitis.

Authors:  I R Mackay; S Weiden; J Hasker
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

6.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

Review 7.  Autoantibodies against cytochromes P450: role in human diseases.

Authors:  P Beaune; D Pessayre; P Dansette; D Mansuy; M Manns
Journal:  Adv Pharmacol       Date:  1994

8.  Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors.

Authors:  P T Donaldson; D G Doherty; K M Hayllar; I G McFarlane; P J Johnson; R Williams
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

9.  Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases.

Authors:  B H Stricker; A P Blok; F H Claas; G E Van Parys; V J Desmet
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

10.  Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis.

Authors:  I W Graziadei; G E Obermoser; N T Sepp; K H Erhart; W Vogel
Journal:  Lupus       Date:  2003       Impact factor: 2.911

View more
  9 in total

1.  When Good Medications Go Bad, Don't DILI Dally.

Authors:  Luke Gessel; Joseph Alcorn
Journal:  Dig Dis Sci       Date:  2016-06       Impact factor: 3.199

2.  Autoimmune hepatitis following drug-induced liver injury in an elderly patient.

Authors:  Junichiro Kumagai; Tatsuo Kanda; Shin Yasui; Yuki Haga; Reina Sasaki; Masato Nakamura; Shuang Wu; Shingo Nakamoto; Makoto Arai; Yotaro Iino; Osamu Yokosuka
Journal:  Clin J Gastroenterol       Date:  2016-05-12

Review 3.  Drug-induced autoimmune hepatitis: A minireview.

Authors:  Chin Kimg Tan; Danielle Ho; Lai Mun Wang; Rahul Kumar
Journal:  World J Gastroenterol       Date:  2022-06-28       Impact factor: 5.374

4.  Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis.

Authors:  Teruko Arinaga-Hino; Tatsuya Ide; Jun Akiba; Hiroyuki Suzuki; Reiichiro Kuwahara; Keisuke Amano; Toshihiro Kawaguchi; Tomoya Sano; Eisuke Inoue; Hironori Koga; Keiichi Mitsuyama; Yasutoshi Koga; Takuji Torimura
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

Review 5.  Recent Advances in the Histopathology of Drug-Induced Liver Injury.

Authors:  David E Kleiner
Journal:  Surg Pathol Clin       Date:  2018-06

Review 6.  Similarities and Differences in Autoimmune Hepatitis Epidemiology between East and West: Autoimmune Hepatitis in East Asia, Southeast Asia, and South Asia.

Authors:  Hirayuki Enomoto; Shuhei Nishiguchi
Journal:  Inflamm Intest Dis       Date:  2017-02-03

7.  The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.

Authors:  Guiqiang Wang; Atsushi Tanaka; Hong Zhao; Jidong Jia; Xiong Ma; Kenichi Harada; Fu-Sheng Wang; Lai Wei; Qixia Wang; Ying Sun; Yuan Hong; Huiying Rao; Cumali Efe; George Lau; Diana Payawal; Rino Gani; Keith Lindor; Wasim Jafri; Masao Omata; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-05-04       Impact factor: 6.047

8.  Drug-Induced Liver Injury Associated with Complementary and Alternative Medicines.

Authors:  Koji Takahashi; Tatsuo Kanda; Shin Yasui; Yuki Haga; Junichiro Kumagai; Reina Sasaki; Shuang Wu; Shingo Nakamoto; Masato Nakamura; Makoto Arai; Osamu Yokosuka
Journal:  Case Rep Gastroenterol       Date:  2016-11-25

9.  Differential characteristics in drug-induced autoimmune hepatitis.

Authors:  Omar Yesid Martínez-Casas; Gabriel Sebastián Díaz-Ramírez; Juan Ignacio Marín-Zuluaga; Octavio Muñoz-Maya; Oscar Santos; Jorge Hernando Donado-Gómez; Juan Carlos Restrepo-Gutiérrez
Journal:  JGH Open       Date:  2018-05-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.